M
M.C. Pietanza
Researcher at Merck & Co.
Publications - 24
Citations - 911
M.C. Pietanza is an academic researcher from Merck & Co.. The author has contributed to research in topics: Pembrolizumab & Pemetrexed. The author has an hindex of 12, co-authored 24 publications receiving 517 citations. Previous affiliations of M.C. Pietanza include Memorial Sloan Kettering Cancer Center.
Papers
More filters
Journal ArticleDOI
Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189.
Delvys Rodriguez-Abreu,Steven Francis Powell,Maximilian Hochmair,Shirish M. Gadgeel,Emilio Esteban,Enriqueta Felip,G. Speranza,F. De Angelis,Manuel Domine,S. Cheng,Helge Bischoff,N. Peled,Martin Reck,Rina Hui,Edward B. Garon,Michael Boyer,Takayasu Kurata,J. Yang,M.C. Pietanza,Fabricio Souza,M.C. Garassino +20 more
TL;DR: Pembrolizumab plus pemetrexed and platinum-based chemotherapy significantly improved overall survival (OS) and progression-free survival (PFS) in patients with previously untreated metastatic nonsquamous non-small-cell lung cancer (NSCLC) as discussed by the authors.
Journal ArticleDOI
Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407
Luis Paz-Ares,Corey J. Langer,Silvia Novello,Balazs Halmos,Ying Cheng,Shirish M. Gadgeel,Rina Hui,S. Sugawara,Hossein Borghaei,Razvan Cristescu,Deepti Aurora-Garg,Andrew Albright,Andrey Loboda,J. Kobie,Jared Lunceford,M. Ayers,Gregory M. Lubiniecki,M.C. Pietanza,Bilal Piperdi,M.C. Garassino +19 more
TL;DR: Paz-Ares et al. as mentioned in this paper explored the relationship between tTMB and efficacy in KEYNOTE-021 C and G (nonsquamous; NCT02039674), 189 and NNNSCLC, and 407 (squamous), respectively, and found that TMB was not significantly associated with efficacy of pembro + chemo or of chemo alone as 1L therapy for metastatic NSCLC.
Journal ArticleDOI
Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trials
Roy S. Herbst,Gabriel Lima Lopes,Dariusz M. Kowalski,Makoto Nishio,Y-L. Wu,G. de Castro Junior,Paul Baas,Dong Wook Kim,Matthew A. Gubens,Razvan Cristescu,Deepti Aurora-Garg,Andrew Albright,M. Ayers,Andrey Loboda,Jared Lunceford,J. Kobie,Gregory M. Lubiniecki,M.C. Pietanza,Bilal Piperdi,Tony Mok +19 more
Journal ArticleDOI
LBA51 KEYNOTE-024 5-year OS update: First-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) ≥50%
Julie R. Brahmer,Delvys Rodriguez-Abreu,A.G. Robinson,Rina Hui,Tibor Csőszi,Andrea Fülöp,Maya Gottfried,Nir Peled,Ali Tafreshi,Sinead Cuffe,Mary O'Brien,Shruti Rao,Katsuyuki Hotta,Ticiana A. Leal,Jonathan W. Riess,Erin Jensen,Bin Zhao,M.C. Pietanza,Martin Reck +18 more
TL;DR: Oncology, Hematology & Oncology and Lungen Clinic, Airway Research Center North, German Center of Lung Research, Grosshansdorf, Germany are used in this study.
Journal ArticleDOI
OA04.06 Evaluation of TMB in KEYNOTE-189: Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy for Nonsquamous NSCLC
M.C. Garassino,Delvys Rodriguez-Abreu,Shirish M. Gadgeel,Emilio Esteban,Enriqueta Felip,G. Speranza,Martin Reck,Rina Hui,Michael Boyer,Razvan Cristescu,Deepti Aurora-Garg,Andrew Albright,Andrey Loboda,J. Kobie,Jared Lunceford,M. Ayers,Gregory M. Lubiniecki,Bilal Piperdi,M.C. Pietanza,Edward B. Garon +19 more